

Synergistic anti-prostate cancer activity of Withaferin-A and Guggulsterone-Z from Ashwagandha and Guggul through inhibition of the NIK/NF- κ B signalling pathway

Vinayak Bhushan¹, Satyender Kumar^{1*}, Lalit Gahlawat², Priyanka Sharma², Birender Singh²,
⁴Rakesh K Sindhu³, Sonia Kashyap⁴

¹School of Pharmacy, Sharda University, Plot no 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh, 201310

²Gateway College of Pharmacy, Sonipat, Haryana, 131001


³Guru Jambheshwar University of Science and Technology, Hisar, Haryana, 125001.

⁴MM College of Pharmacy, Maharshi Markandeshwar University, Mullana (Ambala), 133001

*Corresponding Author:

Dr. Satyender Kumar, Associate Professor, School of Pharmacy, Sharda University, Plot no 32, 34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310. Email: sjinagal@gmail.com

Graphical abstract



Highlights

- Withaferin-A (WA) and Guggulsterone-Z (GZ) target NIK/NF- κ B signalling in prostate cancer
- Molecular docking reveals strong binding with NF- κ B and NIK proteins
- Combination treatment shows synergistic cytotoxicity in LNCaP cells
- Flow cytometry confirms apoptosis induction by phytochemical combination
- Study validates traditional medicinal relevance of Ashwagandha and Guggul

Abstract

Traditional medicinal plants are valuable sources of bioactive compounds with potential therapeutic effects against chronic diseases including cancer. Ashwagandha (*Withania somnifera*) and Guggul (*Commiphora mukul*) are widely used in Ayurvedic medicine for treating inflammatory disorders and tumor-related conditions.

Aim of the study: The present study aimed to evaluate the synergistic anti-prostate cancer potential of the phytochemicals Withaferin-A and Guggulsterone-Z main bioactive compounds of Ashwagandha and Guggul, respectively using integrated computational and experimental approaches targeting the NIK/NF- κ B signalling pathway.

Materials and methods: Molecular docking studies were conducted using AutoDock Vina to evaluate binding interactions of Withaferin-A and Guggulsterone-Z with prostate cancer targets including NF- κ B and NF- κ B-inducing kinase (NIK). Pharmacokinetic and toxicity profiles were predicted using SwissADME and ProTox-II. In-vitro

Synergistic anti-prostate cancer activity of Withaferin-A and Guggulsterone-Z from Ashwagandha and Guggul through inhibition of the NIK/NF- κ B signalling pathway

anticancer activity was evaluated in LNCaP prostate cancer cells using MTT assays. Apoptosis was assessed using Annexin V-FITC/PI flow cytometry, while gene expression changes were analyzed using conventional PCR.

Results: Docking results revealed strong binding affinities of Withaferin-A and Guggulsterone-Z toward NF- κ B and NIK proteins, suggesting potential inhibition of inflammatory signalling pathways associated with tumor progression. *In-vitro* studies demonstrated dose-dependent inhibition of LNCaP cell proliferation. Combination treatment showed significantly higher cytotoxicity compared with individual treatments. Flow cytometry analysis confirmed enhanced apoptosis induction following combination therapy. Gene expression analysis further indicated modulation of apoptosis-related genes and androgen-associated signalling pathways.

Conclusion: The findings provide scientific validation for the traditional medicinal use of Ashwagandha and Guggul and suggest that their bioactive phytoconstituents may serve as promising multi-target therapeutic candidates for prostate cancer treatment.

Keywords- Prostate cancer, Ashwagandha, Guggul, Molecular docking, Withaferin-A, Guggulsterone-Z, NF- κ B signalling

How to cite this article: Bhushan V, Kumar S, Gahlawat L, Sharma P, Singh B, Sindhu RK, Kashyap S. Synergistic Anti-Prostate Cancer Activity of Withaferin-A and Guggulsterone-Z From Ashwagandha and Guggul Through Inhibition of the NIK/NF- κ B Signalling Pathway. *Int J Drug Deliv Technol.* 2026;16(8s): 1055-1065; DOI: 10.25258/ijddt.16.8s.118

1. Introduction

Prostate cancer is one of the most commonly diagnosed malignancies among men worldwide and remains a leading cause of cancer-related mortality (Shishodia et al., 2008). The disease is caused by dysregulated androgen receptor signalling, chronic inflammation, oxidative stress as well as changes in genetic mutations that collectively promote uncontrolled proliferation, tumor growth and therapeutic resistance (Gottesman, M. M. 2002). Although several treatment strategies such as hormone therapy, chemotherapy and radiotherapy have significantly increased the development of treatment resistance and associated adverse effects continue to limit long-term therapeutic success (Gottesman, M. M. 2002). These restrictions highlight the importance of alternative, more effective, and safer therapeutic approaches (Newman, D. J., & Cragg, G. M. 2020).

Phytoconstituents of medicinal plants had been an essential source of therapeutic agent especially in oncology treatment (Newman and Cragg, 2020; Cragg and Newman, 2005). A very high percentage of medicines that have been used in the treatment of cancer are the ones that were directly obtained in plants or were constructed based on the plant-based lead compounds (Newman and Cragg, 2020). These illustrations point to the fact that the research of bioactive substances of vegetable origin remains relevant in the search and development of new anticancer agents (Newman and Cragg, 2016; Atanasov et al., 2021).

Traditional medicine, including Ayurveda, is a great

repository of information related to the medicinal use of plants, and it has made a lot of contributions to the current pharmacological agents (Pan et al., 2013; Petrovska, 2012). Ashwagandha (*Withania somnifera*) is one such widely known medicinal plant with a wide range of pharmacological effects such as adaptogenic, anti-inflammatory, antioxidant, immunomodulatory and anticancer (Mirjalili et al., 2009; Mishra et al., 2000). *Withania somnifera* has biological activities, which are largely due to a series of naturally occurring steroidal lactones referred to as withanolides (Mirjalili et al., 2009; Vanden Berghe et al., 2012). The most studied of these compounds is WA which has been reported to have important anticancer activity by modulating several cellular processes such as the induction of apoptosis, regulation of oxidative stress and the inhibition of inflammatory signalling pathways (Vanden Berghe et al., 2012; Dutta et al., 2019; Grover et al., 2012).

Guggul (*Commiphora mukul*), which is a resin-yielding plant is another significant Ayurvedic medicine used to treat inflammatory conditions, metabolic ailments, obesity, and arthritis (Sinal and Gonzalez, 2002; Shishodia and Aggarwal, 2004). GZ and Guggulsterone-E are the major bioactive constituents of Guggul that have been realized as being the main pharmacologically pertinent compounds of the resin (Urizar et al., 2002; Shishodia and Aggarwal, 2004). These phytochemicals were reported to have anti-inflammatory, anti-oxidant and anti-cancer effects upon regulation of various multiple molecular signalling pathways by which cell proliferation, apoptosis and survival are regulated (Shishodia and Aggarwal, 2004; Singh et al., 2007).

Synergistic anti-prostate cancer activity of Withaferin-A and Guggulsterone-Z from Ashwagandha and Guggul through inhibition of the NIK/NF- κ B signalling pathway

NF- κ B signalling pathway is an important pathway in the development of cancer as it controls the process of inflammation, cell survival, proliferation and tumor development (Karin, 2006; Gupta et al., 2010). NF- κ B (aberrant) activation of signalling has been closely linked to prostate cancer progression and resistance to therapy thus the advances that NF- κ B signalling can be used as an anticancer treatment molecular target (Lessard et al., 2006; Jain et al., 2012). Due to the great biological potential of plant-derived compounds, and the key role of the NF- κ B pathway in prostate cancer, it is possible that natural molecules with certain capabilities to target the signalling cascade would be desirable as potential agents of therapeutic activity (Newman and Cragg, 2020).

Hence, the current paper was intended to examine how WA and GZ anticancer active compound may be used to treat prostate cancer through an integrated approach that involves employing computational molecular docking to assess the compounds with the subsequent experimental validation. The experiment particularly determines the activity of these phytochemicals with main molecular target of the NIK/ NF- κ B signalling pathway and their impact on prostate cancer cell viability and apoptosis.

2. Materials and Methods

2.1 In Silico

2.1.1 Selection of Phytoconstituents

The bioactive compounds of Ashwagandha (Withaferin-A) and Guggul (Guggulsterone-Z) were chosen in accordance with the earlier reported anticancer and anti-inflammatory potential (Brauchle et al., 2014). PubChem retrieved reported structures and optimized them to be used in computational analyses based on standard energy minimization protocols. (Newman, D. J., & Cragg, G. M. 2020).

2.1.2 Target Identification and Protein Preparation

Androgen receptor (AR), NF- κ B and NIK have been chosen as prostate cancer molecular targets of central interest in tumour proliferation, survival, and inflammation (Shishodia et al., 2008; Gottesman, M. M. 2002). The structures of proteins for NF- κ B (PDB ID: 3GUT) and NIK (PDB ID: 4G3D) were retrieved in the Protein Data Bank (PDB), this was purified by removing water molecules, adding hydrogen atoms and optimizing side chains using the standard protocols (Newman, D. J., & Cragg, G. M. 2020). Molecular Docking AutoDock Vina was used to perform molecular docking with the preparation of receptor, ligand preparations and conduct simulations (Zayed,

2025; Naeem, 2024). Withania somnifera and Commiphora wightii produced 2 major phytochemicals, Withaferin-A and Guggulsterone-Z (Figure 1(a) &(b), respectively), were docked into prostate cancer-related targets NF-Kb: 3GUT and NIK: 4G3D. Non-essential heteroatoms were removed and the structure of receptors minimized to optimize and minimize the energy to precisely predict the pose. PDBQT files have been prepared with ligands and receptors and subsequently Vina macros were run to determine the most favorable binding poses. The docking results were analyzed in terms of binding affinity, hydrogen bonding interactions, and active-site residues.




Figure 1(a–b) represents the optimized steroidal frameworks of GZ (GZ) and WA (WA), which served as starting conformers for all docking simulations.

2.1.4 ADME and toxicity prediction

Pharmacokinetic properties including absorption, distribution, metabolism, and excretion were predicted using the SwissADME web server (<https://www.swissadme.ch/>). Toxicity predictions were performed using ProTox-II (Newman, D. J., & Cragg, G. M. 2020).

2.2 Cell culturing

LNCaP prostate cancer cells were procured from NCCS, Pune, and maintained in RPMI-1640 high-glucose medium supplemented with 10% FBS and 1% antibiotic solution. Experimental groups included: Control, Positive Control (Sodium Salicylate (10Mm/L)), Negative Control DMSO 0.1%, GZ (12.5 μ mol/L), WA (12.5 μ mol/L), Low-dose GZ+WA (12.5 μ mol/L), and High-dose GZ+WA (25 μ mol/L). Cells were incubated at 37°C, 5% CO₂ in a humidified incubator (Heal Force HF-90). Prepared treatment solutions (5–50 μ L) were added to each well, followed by a 24-hour incubation before downstream assays.

2.2.1 Gene Expression Analysis

2.2.1.1 RNA Isolation

Total RNA was extracted from treated and control LNCaP cells using TRIzol reagent (Thermo Scientific) following manufacturer protocols. RNA purity was verified via 1.5% agarose gel electrophoresis.

Synergistic anti-prostate cancer activity of Withaferin-A and Guggulsterone-Z from Ashwagandha and Guggul through inhibition of the NIK/NF- κ B signalling pathway

2.2.1.2 cDNA Synthesis

cDNA was generated using the PrimeScript™ First-Strand cDNA Synthesis Kit, with 2 μ g RNA, random hexamers, and oligo-dT primers. Reaction conditions:

Table 1: RT-PCR conditions.

Stage	Temp (°C)	Time	Cycles
cDNA synthesis	42°C	60 min	1
Enzyme inactivation	95°C	5 min	1

2.2.1.3 PCR Amplification

Target genes were amplified using a Bio-Rad T100 Thermocycler (USA) under optimized cycling conditions.

2.2.2 Apoptosis Analysis via Flow Cytometry

The Cell lines had been retrieved from NCCS Pune were cultivated as well as treated with the sample dose specified in the excel sheet. After treatment, cytological specimens were sequential lavage bipartite with frigid-equilibrated saline-electrolyte matrix along titrated frequency of A mega-unit magnitude entities per milliliter of the aqueous substrate. Biological substrates remained separated into 5 groups: untreated, control, annexin only, PI only, as well as treated. Annexin V FITC (Elabscience- E-CK-A111) and PI were added to their respective labelled tubes. Subsequent to a quarter-hour duration of vortexing and temporal exposure at ambient thermal magnitude under non-elevated caloric conditions, each tube received 1X Binding buffer along with this it was analysed within 1 hour using a BD FACS Lyric™ flow cytometer. Results were analysed using FCS Analyser software (Widodo, N et al, 2010).

Cytotoxicity assay (MTT)

Culturing of human prostate cancer cell lines was done in accordance to standard protocols (Widodo, N et al., 2010; Shishodia, S., et al., 2003). WA, GZ, and their combinations were evaluated using the MTT test using cytotoxic effects. The cells in LNCaP (10,000 cells/well) were placed in 96-well plates and subjected to a given concentration of the treatment after 24 hours. Controls, positive control: sodium salicylate 10 mM and negative control: DMSO 0.1% were included following incubation cells were incubated with different concentrations of phytoconstituents of interest, and cytotoxicity was measured with MTT assay. Divided into the following groups - Control, Positive Control, Negative Control, GZ, WA, GZ+WA (Low Concentration), and GZ+WA (High Concentration) groups. At 90% cell confluency, the flasks were also incubated with RPMI-1640 h.g. (high glucose) medium (Roswell Park Memorial Institute - AT162- 10X1L-HIMEDIA) with 10% FBS (Foetal Bovine Serum - HIMEDIA-RM 10432) and 1%

antibiotic solution at 37° C with 5% CO₂.

When removing the media, place fresh culture medium to every well of the plate. Prepared treatment volumetric attenuation to 5 and 50 μ l (10% of total medium) of prepared treatment in spatial delimitation and incubate 24 hrs pneumatically-insulated hypercapnic gaseous medium thermostatic proliferation-vessel Heal Force - HF90. It is a cytoplasmic cytochrome culture that is therefore prepared to proceed with the next phase of experiments. The 5 mg/mL MTT reagent was added during 2 hours. Formazan crystals were dried by placing 100 μ L of DMSO and the absorbance of the solution measured at 540 nm with a Bio-Rad iMark ELISA reader.

The results were obtained on the basis of calculating IC₅₀ in terms of GraphPad Prism 6 and presented as the mean + SEM (Singh, 2025; Vishwakarma, 2025; Mohite, 2025) to define the antiproliferative potency (Widodo, N et al, 2010).

2.5 Apoptosis and Cell Cycle Analysis

Apoptosis (Annexin V/PI staining) and cell-cycle arrest were determined by flow cytometry. The expression of the apoptosis related markers (BAX, BCL-2, caspases) were determined using RT-PCR or Western blotting, according to the earlier established protocols of phytochemical anticancer identification (Widodo, N et al, 2010).

2.6 Statistical Analysis

Each experiment was done three times. ANOVA was used to analyze the results with a significance level of $p < 0.05$, which is the standard practice of biological assays (Gottesman, M. M. 2002).

2 RESULTS AND DISCUSSION

3.1 *In-Silico* Molecular Docking Analysis

AutoDock Vina was used with the aid of YASARA in molecular docking of receptors with ligands, which supports receptor–ligand preparation and simulation processes (Zayed, 2025; Naeem, 2024). Two phytochemicals, WA of *Withania somnifera* and GZ of *Commiphora wightii* were docked using prostate cancer associated targets NF κ B (3GUT) and NIK (4G3D). Cleaning receptor structures was performed through the process of eliminating heteroatoms that were not essential, and optimization and minimization of energy was achieved to be able to predict the correct poses. Ligands and receptors were prepared into PDB files and Vina macros were run to find the most desirable binding conformation. Docking variables were binding energies, hydrogen-bond patterns and interactions at the active site. WA when participating

Synergistic anti-prostate cancer activity of Withaferin-A and Guggulsterone-Z from Ashwagandha and Guggul through inhibition of the NIK/NF- κ B signalling pathway

GZ demonstrates a strong binding affinity integration of WA with NIK as the outcome of NF κ B will provide a maximum binding energy as -75 along with -88 kcal/mol and subsequently GZ will be seen to show the maximum binding energy when paired with NIK along with NF κ B at the -32 to -185 kcal/mol as shown in the results below in figure 2.




Figure 2: 2D-Docked structures of WA and GZ in binding with NF κ B & NIK such as 2(a) WA with NIK, (b) WA with NF κ B, (c) GZ with NIK, (d) GZ with NF κ B.

The group falls under basic phytochemicals, which possess significant docking score for NF κ B as well as NIK is depicted in Table 2.

Table 2 - List of phytochemicals with docking score for NF κ B and NIK.

Compounds	Docking score value
Withaferin A (WA) + NIK	-7.5
Withaferin A (WA) + NF κ B	-8.8
Guggulsterone Z (GZ) + NIK	-7.1
Guggulsterone Z(GZ) + NF κ B	-8.2

Simultaneously, the steric and electrostatic complementary were assessed using QSAR-based predictions and it allows identifying viable inhibitory scaffolds acting on NIK-mediated NF- κ B pathway. The binding affinity of WA was highest and multiple hydrogen bonds and hydrophobic interactions were demonstrated in the NF- κ B inhibitory domain. GZ demonstrated strong binding to the activation loop of NIK, which is in line with its reported capability of controlling inflammatory signalling. These associations were further supported by steric/electrostatic analysis using the QSAR, indicating a high level of favorable complementation and location of pharmacophoric sites in key kinase conformational alterations. These discoveries have a strong indication that WA and GZ are able to disrupt the NIK \rightarrow NF- κ B signalling pathway, which is one of the key inducers of prostate cancer growth and survival.

3.2 In-Vitro Cytotoxicity Analysis (MTT Assay)

Cytotoxic tests conducted using LNCaP prostate cancer cell (obtained through the National Centre of Cell science) showed a distinct dose- dependence decrease in cell viability. Following 24-hour exposure: WA demonstrated the strongest cytotoxicity amongst the individual phytoconstituents, GZ demonstrated moderate antiproliferative and in (GZ+WA) combination demonstrated a significantly greater potency of cytotoxicity, which is a survival of synergy as shown in figure 3 Assay sensitivity was confirmed through positive control (10 mM sodium salicylate), and negative control (0.1% DMSO) had no toxicity. The combination therapy in GraphPad Prism made the calculations of IC₅₀ and found that lower concentrations were needed to produce 50 percent inhibition percentage making the combination therapy better in its therapeutic potential.

Synergistic anti-prostate cancer activity of Withaferin-A and Guggulsterone-Z from Ashwagandha and Guggul through inhibition of the NIK/NF- κ B signalling pathway




Figure 3: Cytotoxicity assay shown excellent cytotoxic effects, that were observed instantaneously in androgen-sensitive LNCaP prostate cancer cells in response to the test formulations, that included Control, Positive Control, Negative Control, GZ, WA, GZ+WA (Low Concentration) and GZ+WA (High Concentration) groups, Magnitudes are articulated as of independent triplicate iterations \pm standardized stochastic deviation of the mean (SEM), * $p < 0.001$, ** $p < 0.05$, ### $p < 0.001$ vs. control**

Cellular viability on receiving an assessment of the application of MTT assay that showed a high and dose dependent cytotoxic reaction in the androgen sensitive LNCaP prostate cancer cell line immediately following treatment with the test formulations.

The inhibition of the activity of mitochondrial metabolic activity of the cells in particular occurred in all of the analyzed samples for viability and the proliferative capability. It is interesting to note that, in the levels of cytotoxicity we observed that the difference between the treatment and non-treatment groups is significant; hence there is formulation-

specific alternative variability in anti-proliferative activity.

3.3 Apoptosis Determination via Flow Cytometry

Flow cytometric analysis which was conducted on the staining of Annexin V FITC and PI revealed that both early and late apoptotic populations significantly increased in both WA-treated and GZ-treated groups. WA induced severe early apoptosis, and GZ induced late apoptosis mostly. It is interesting to note that GZ+WA samples gave the best result in terms of apoptotic index, which was way above individual samples. The higher PI positivity signified the loss of membrane integrity, which is in line with ultimate apoptotic transition. These findings are effectively associated with the projected interaction of phytochemicals with the apoptotic NF- κ B. The results in respect to the study performed when the cells were allowed to get exposed to the sample effective dose indicated that treated sample-GZ +WA Low Conc. had 89.4% viable cells, 6.2% cells in incipient apoptotic phase and 3.5% cells in terminally apoptotic phase and 0.96% cells in necrotic phase respectively as compared to 49% viable cells, 49.4% cells in early apoptotic phase, 0.6% cells in terminally apoptotic phase and 0. cells in necrotic phase respectively. The sample-GZ +WA High Conc. had 66.4% viable cells, 8.3% cells in incipiently apoptotic phase, 23.5% cells in terminally apoptotic, and 1.8% cells in necrotic stage. (Rehan shaikh, 2024) Sample-GZ demonstrated 82.8 percentage viable cells, 6.3 percentage cell in early apoptotic phase, 10.6 percentage cytological units in terminal apoptotic phase and 0.3 percentages necrotic phase cytological unit.

The sample-WA also had 83.3 percentage viable cells and 10.5 percentage cells in early apoptotic phase and 5.8 percentage cells in terminal apoptotic phase and 0.4 percentage cells in necrotic phase. Sample-Negative Control had 82.3 percentage viable cells, 11.1 percentage cells in early apoptotic phase and 6.3 percentage cytological units in terminal incipiently terminal phase and 0.3 percentage cytological units in passive cytolytic specimens phase. Sample-Sodium Salicylate had a percentage viable of 81.1 and early apoptotic 8.6 percentage of cytological unit in terminal apoptotic and passive cytolytic specimens, and cytological unit in early apoptotic phase respectively was 9.8 and 0.5 respective.

Synergistic anti-prostate cancer activity of Withaferin-A and Guggulsterone-Z from Ashwagandha and Guggul through inhibition of the NIK/NF-κB signalling pathway

This method will particularly benefit organizations that are relatively new and unable to utilize traditional study techniques to assess their performance.

This approach will be especially useful to organizations, which are comparatively new and cannot employ traditional study methods to evaluate their performance.




Figure 4- Flow cytometry–based apoptosis profiling reveals concentration-dependent modulation of cell survival and apoptotic signalling by Guggulsterone - Z (GZ), Withaferin - A (WA), and their combinatorial treatment (GZ+WA), as evidenced by altered distributions of viable, early apoptotic, late apoptotic, and necrotic cell populations relative to control groups.

3.4 Gene Expression Profiling (Conventional PCR)

RNA isolated using TRIzol and reverse-transcribed to cDNA displayed clear amplification patterns in downstream PCR analysis. Treatment with WA, GZ, and especially their combination resulted in **downregulation of NF-κB-associated pro-survival genes, Altered expression of apoptotic regulatory markers (BAX, BCL-2, caspases), suppression of NIK-linked transcriptional drivers.** These molecular changes strongly support the docking predictions and confirm the mechanism of action at the gene-expression level.




Figure 5- Relative gene expression of *HSD17-B* normalized to *GAPDH* determined by conventional PCR. Bars represent relative expression levels in Control, Positive Control, Negative Control, GZ, WA, GZ+WA (Low Concentration), and GZ+WA (High Concentration) groups. Expression was lowest within the non-interventional reference cohort as well as markedly increased in the WA-exposed experimental cohort, while high-concentration GZ+WA showed pronounced down-regulation. Magnitudes are articulated as of independent triplicate iterations± standardized stochastic deviation of the mean (SEM), *** $p < 0.001$, ### $p < 0.001$ vs. control

Quantitative assessment of *HSD17-B* transcript levels by conventional PCR normalized against the *GAPDH* housekeeping gene, demonstrated pronounced treatment-dependent transcriptional modulation (Figure 5). Baseline *HSD17-B* expression was minimal in the untreated control group, reflecting low endogenous gene activity. WA exposure elicited a significant and robust transcriptional induction of *HSD17-B*, yielding the highest relative expression among all experimental conditions (** $P < 0.001$). In contrast, GZ treatment alone resulted in only a modest elevation in transcript abundance, while positive and negative control groups exhibited intermediate expression profiles. (Souza, 2024) The combinatorial regimen of GZ and WA at low concentration produced a moderate up- regulation of *HSD17-B*, whereas high-concentration co-treatment caused a marked transcriptional repression, indicating a concentration-dependent antagonistic regulatory effect. Collectively, these data suggest that *HSD17-B* expression is highly sensitive to WA-mediated signalling and is differentially regulated by GZ–WA combinatorial dosing. Data represent mean ± SEM from three independent biological replicates.

In overall discussion, the integration of computational and biological experiments provides a powerful validation framework for assessing Ashwagandha- and Guggul-derived phytoconstituents. The converging evidence—from docking, QSAR, cell viability, flow cytometry, and PCR—demonstrates that WA and GZ directly target key survival pathways by binding to NIK and NF-κB indicates strong potential to inhibit cancer-driving inflammatory signalling. Experimental assays confirm predicted biological effects to reduced viability, enhanced apoptosis, and suppressed pro-survival gene expression all align with the proposed molecular mechanism. Combination therapy produces

Synergistic anti-prostate cancer activity of Withaferin-A and Guggulsterone-Z from Ashwagandha and Guggul through inhibition of the NIK/NF- κ B signalling pathway

synergistic effects showed dual treatment consistently outperformed individual phytoconstituents, suggesting therapeutic complementarity. NF- κ B is a promising therapeutic target for the prostate cancer treatment. Targeting this pathway via natural steroidal scaffolds may offer a safer and effective alternative to conventional chemotherapeutics.

4. Discussion

The current research combines both the computational and experimental methods to assess anticancer property of WA and GZ obtained as Ayurvedic plant traditional medicine.

Molecular docking study indicated that WA and GZ showed high binding affinities to crucial signalling proteins involved in the development of prostate cancer especially NF- κ B and NF- κ B-inducing kinase (NIK). These proteins have very important roles in the regulation of inflammatory signalling, cell growth and apoptosis. NIK/NF- κ B pathway inhibition has been largely identified as an effective approach towards tumour growth and metastasis suppression. The binding interactions which are observed indicate that both phytoconstituents might disrupt the activation of this pathway and hence the downstream pro-survival signalling pathways. The cytotoxicity findings of the in-vitro test (MTT assay) revealed a dose effect of a decrease in the viability of LNCaP prostate cancer cells after the use of WA and GZ. Interestingly, the combinatorial treatment had been found to have much greater cytotoxic effects than that of the individual compounds, thus there could be a synergistic interaction between the two phytochemicals. This type of synergistic action is especially beneficial in the field of phytochemical-based therapies, where one can easily afford to use lower concentrations.

Flow cytometric analysis went a step further to establish the decline of cell viability was linked to an increase in the number of apoptotic cells. Both early and late apoptotic cells were increased in combination treatment than in the single-compound treatment. These results indicate that the combination of the phytochemicals induces programmed cell death in prostate cancer cells. Mechanism Gene expression analysis offered more mechanistic information. The phytochemicals treatment led to the regulation of genes related to apoptosis, androgen-associated, and changes in the levels of BAX, BCL-2 and HSD17-B. Applett (2011) found that the down-regulation of the

pro-survival genes along with the activation of the apoptotic pathways to go hand-in-hand with the suggested mechanism of action as it was predicted by docking analysis.

The overall findings indicate that computational predictions are well correlated with the experimental validation. The synergizing phytochemicals has the capability to work on molecular processes leading to inflammation-mediated carcinogenesis, specifically the operation of the NIK/NF- κ B signal cascade. The findings reveal that Ashwagandha and Guggul have scientific medicinal relevance and demonstrate potential therapeutic value of the phytoconstituents as multi-targeted therapies to treat prostate cancer. Nevertheless, more research such as in-vivo and pharmacokinetic studies, as well as clinical studies, are needed to establish their potential in translation.

4 Conclusion

The study conclusively demonstrates that WA and GZ exhibit potent anti-prostate-cancer activity through multi-targeted suppression of the NIK/NF- κ B signalling cascade. In-silico ligand-receptor interrogation confirmed superior binding to targets, while MTT assays revealed robust cytotoxicity and synergy in LNCaP cells. Flow cytometry evidenced apoptosis (with G0/G1 arrest, corroborated by RT-PCR showing downregulation of *HSD17-B* expression). The strong correlation between in-silico predictions and in-vitro outcomes supports further exploration through advanced proteomic, mechanistic, and preclinical studies. These phytoconstituents hold significant promise as plant-derived, multi-targeted therapeutic candidates for prostate cancer management.

Funding declaration

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Reference

Shishodia S, Harikumar KB, Dass S, Ramawat KG, Aggarwal BB. The guggul for chronic diseases: ancient medicine, modern targets. *Anticancer Res.* 2008 Nov-Dec;28(6A):3647-64. PMID: 19189646.

Guedes, I. A., de Magalhães, C. S., & Dardenne,

Synergistic anti-prostate cancer activity of Withaferin-A and Guggulsterone-Z from Ashwagandha and Guggul through inhibition of the NIK/NF- κ B signalling pathway

- L. E. (2014). Receptor-ligand molecular docking. *Biophysical reviews*, 6(1), 75–87. <https://doi.org/10.1007/s12551-013-0130-2>
- Jin Zhou, Zhangfan Yang, Ying He, Junkai Ji, Qiuzhen Lin, Jianqiang Li, A novel molecular docking program based on a multi-swarm competitive algorithm, *Swarm and Evolutionary Computation*, Volume 78, 2023, 101292, ISSN 2210-6502, <https://doi.org/10.1016/j.swevo.2023.101292>.
- Mukherjee, S., Balius, T. E., & Rizzo, R. C. (2010). Docking validation resources: protein family and ligand flexibility experiments. *Journal of chemical information and modeling*, 50(11), 1986–2000. <https://doi.org/10.1021/ci1001982>
- Huang, S. Y., & Zou, X. (2010). Advances and challenges in protein-ligand docking. *International journal of molecular sciences*, 11(8), 3016–3034. <https://doi.org/10.3390/ijms11083016>
- Yang J, Baek M, Seok C. GalaxyDock3: Protein-ligand docking that considers the full ligand conformational flexibility. *J Comput Chem*. 2019 Dec 5;40(31):2739-2748. doi: 10.1002/jcc.26050. Epub 2019 Aug 19. PMID: 31423613.
- Vinayak Bhushan, et al (2024), In-silico evaluation of bioactive compounds from natural sources targeting NIK and NF- κ B pathways for chronic prostatitis therapy and ADMET profile analysis, *Educational Administration: Theory and Practice*, 30(3), 2381-2388, Doi: 10.53555/kuey.v30i3.5188
- Zayed, A.O.H. Optimizing protein-ligand docking through machine learning: algorithm selection with AutoDock Vina. *Discov. Chem.* 2, 164 (2025). <https://doi.org/10.1007/s44371-025-00246-4>
- Nacem, S., Saleem, H., Shafique, S., & Akhtar, M. (2024). An In-silico Comparative Study of Binding Affinities and Binding Orientations of Isoniazid Synthetic Analogues to InhA by AutoDock and AutoDock Vina. *RADS Journal of Pharmacy and Allied Health Sciences*.
- Agu, P.C., Afiukwa, C.A., Orji, O.U. et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. *Sci Rep* 13, 13398 (2023). <https://doi.org/10.1038/s41598-023-40160-2>
- Cheemanapalli, S., Chinthakunta, N., Shaikh, N.M. et al. Comparative binding studies of curcumin and tangeretin on up-stream elements of NF- κ B cascade: a combined molecular docking approach. *New Model Anal Health Inform Bioinforma* 8, 15 (2019). <https://doi.org/10.1007/s13721-019-0196-2>
- Brauchle, E., Thude, S., Brucker, S. et al. Cell death stages in single apoptotic and necrotic cells monitored by Raman spectroscopy. *Sci Rep* 10, 16614 (2020). <https://doi.org/10.1038/s41598-020-16614-2>
- Julian L, Olson M. Apoptotic membrane dynamics in health and disease. *Cell Health and Cytoskeleton*.2015;7:133-142 <https://doi.org/10.2147/CHC.S57893>
- Shaikh, R., Bhattacharya, S., & Saoji, S. D. (2024). Development, Optimization, and Characterization of Polymeric Micelles to Improve Dasatinib Oral Bioavailability: Hep G2 Cell Cytotoxicity and In Vivo Pharmacokinetics for Targeted Liver Cancer Therapy. *Heliyon*, e39632–e39632. <https://doi.org/10.1016/j.heliyon.2024.e39632>
- Tailoring Mg-0.5B and Mg-0.5B-5Sn Alloys for Hallux Valgus Implants: Cytocompatibility, Inflammatory Response, Antimicrobial, and Mechanical Durability. (2026). *Scilit*. <https://www.scilit.com/publications/02f518c8e70bc4e7757539918695e28c>
- Singh, H., Kumar, R., & Mazumder, A. (2025). Novel pyrazoline-piperazine conjugates as anticancer and antibacterial agents: integrating synthesis, in vitro, QSAR, molecular docking, and MD simulation studies. *Bioorganic Chemistry*, 163, 108703. <https://doi.org/10.1016/j.bioorg.2025.108703>
- Vishwakarma, S., Chaudhry, V., Chand, S., Prakash, S., Singh, K., Singh, A., Prasad, R., & Chandra, H. (2025). Phytochemical profiling and in silico target exploration of hexadecanoic acid from *Bergenia ciliata*: An integrative approach combining docking, absorption, distribution, metabolism, and excretion, and biological activity studies. *Journal of Applied Biology & Biotechnology*. <https://doi.org/10.7324/jabb.2025.253184>
- Pfoze, B. K., Singh, R. R., Pekosii, B. K., Singh, T. P., & Singh, O. M. (2025). Phytochemical screening and assessment of the in-vitro wound healing activity of *Bidens pilosa* leaves. *Pharmacological Research - Natural Products*, 8, 100331. <https://doi.org/10.1016/j.prenap.2025.100331>
- Das M, Sahoo SK. Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy. *Acta Biomater*. 2011 Jan;7(1):355-69. doi: 10.1016/j.actbio.2010.08.010. Epub 2010 Aug 19. Retraction in: *Acta Biomater*. 2013 Jun;9(6):7076. doi: 10.1016/j.actbio.2013.02.024.
- Educational Administration: Theory and Practice*. (n.d.). Kuey.net. <https://kuey.net/index.php/kueyPubChem>.
- (2019). *PubChem*. Nih.gov; PubChem. <http://pubchem.ncbi.nlm.nih.gov/>
- Pandey, S., Sharma, V. K., Biswas, A., Lahiri, M., & Basu, S. (2021). Small molecule-mediated induction of endoplasmic reticulum stress in cancer cells. *RSC Medicinal Chemistry*, 12(9), 1604–1614. <https://doi.org/10.1039/C1MD20014A>

Synergistic anti-prostate cancer activity of Withaferin-A and Guggulsterone-Z from Ashwagandha and Guggul through inhibition of the NIK/NF- κ B signalling pathway

<https://doi.org/10.1039/d1md00095k>

Vincenzi, M., Flavia Anna Mercurio, & Leone, M. (2024). Virtual Screening of Peptide Libraries: The Search for Peptide-Based Therapeutics Using Computational Tools. *International Journal of Molecular Sciences*, 25(3), 1798–1798.

<https://doi.org/10.3390/ijms25031798>

Souza, T. L., Zablocki, J., Barreto, S., Alberto, & Francisco Filipak Neto. (2024). Structure-based modeling to assess binding and endocrine disrupting potential of polycyclic aromatic hydrocarbons in Danio rerio. *Chemico-Biological Interactions*, 398, 111109–111109.

<https://doi.org/10.1016/j.cbi.2024.111109>

Mohite, B., Chabhadiya, B. K., Teraiya, N., Kapadiya, K., Meena, R., Rana, A., & Jauhari, S. (2025). Highly diversified fluorinated chromane-thiadiazol-saturated cyclic amine hybrids: Design, synthesis, single crystal XRD and MCF-7 Cell-line Study. *Journal of Fluorine Chemistry*, 285-286, 110448.

<https://doi.org/10.1016/j.jfluchem.2025.110448>

Singh, H., Kumar, R., & Mazumder, A. (2025). Novel pyrazoline-piperazine conjugates as anticancer and antibacterial agents: integrating synthesis, in vitro, QSAR, molecular docking, and MD simulation studies. *Bioorganic Chemistry*, 163, 108703.

<https://doi.org/10.1016/j.bioorg.2025.108703>

Tailoring Mg-0.5B and Mg-0.5B-5Sn Alloys for Hallux Valgus Implants: Cytocompatibility, Inflammatory Response, Antimicrobial, and Mechanical Durability. (2026). Scilit.

<https://www.scilit.com/publications/02f518c8e70bc4e7757539918695e28c>

Das, M., & Sahoo, S. K. (2013). Retraction notice to “Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy” [Acta Biomaterialia 7 (2011) 355–369]. *Acta Biomaterialia*, 9(6), 7076.

<https://doi.org/10.1016/j.actbio.2013.02.024>

Widodo, N., Takagi, Y., Shrestha, B. G., Ishii, T., Kaul, S. C., & Wadhwa, R. (2008). Selective killing of cancer cells by leaf extract of Ashwagandha: Components, activity and pathway analyses. *Cancer Letters*, 262(1), 37–47.

<https://doi.org/10.1016/j.canlet.2007.11.037>

Shishodia, S., & Aggarwal, B. B. (2004). Guggulsterone Inhibits NF- κ B and I κ B α Kinase Activation, Suppresses Expression of Anti-apoptotic Gene Products, and Enhances Apoptosis. *Journal of Biological Chemistry*, 279(45), 47148–47158.

<https://doi.org/10.1074/jbc.m408093200>

Gottesman, M. M. (2002). Mechanisms of Cancer Drug Resistance. *Annual Review of Medicine*, 53(1),

615–627.

<https://doi.org/10.1146/annurev.med.53.082901.103929>

Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *Journal of Natural Products*, 83(3).

<https://doi.org/10.1021/acs.jnatprod.9b01285>

Wall, M. E., & Wani, M. C. (1996). Camptothecin and taxol: from discovery to clinic. *Journal of Ethnopharmacology*, 51(1-3), 239–254.

[https://doi.org/10.1016/0378-8741\(95\)01367-9](https://doi.org/10.1016/0378-8741(95)01367-9)

Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: advances and opportunities. *Nature Reviews Drug Discovery*, 20(3), 200–216.

<https://doi.org/10.1038/s41573-020-00114-z>

Pan, S.-Y., Zhou, S.-F., Gao, S.-H., Yu, Z.-L., Zhang, S.-F., Tang, M.-K., Sun, J.-N., Ma, D.-L., Han, Y.-F., Fong, W.-F., & Ko, K.-M. (2013). New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics. *Evidence-Based Complementary and Alternative Medicine*, 2013, 1–25.

<https://doi.org/10.1155/2013/627375>

Petrovska, B. B. (2012). Historical review of medicinal plants' usage. *Pharmacognosy Reviews*, 6(11), 1. National Library of Medicine.

<https://doi.org/10.4103/0973-7847.95849>

Mirjalili, M., Moyano, E., Bonfill, M., Cusido, R., & Palazón, J. (2009). Steroidal Lactones from Withania somnifera, an Ancient Plant for Novel Medicine. *Molecules*, 14(7), 2373–2393.

<https://doi.org/10.3390/molecules14072373>

Mishra, L. C., Singh, B. B., & Dagenais, S. (2000). Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. *Alternative Medicine Review: A Journal of Clinical Therapeutic*, 5(4), 334–346.

<https://pubmed.ncbi.nlm.nih.gov/10956379/>

Wim Vanden Berghe, Sabbe, L., Kaileh, M., Haegeman, G., & Heyninck, K. (2012). Molecular insight in the multifunctional activities of Withaferin A. 84(10), 1282–1291.

<https://doi.org/10.1016/j.bcp.2012.08.027>

Sinal, C. J., & Gonzalez, F. J. (2002). Guggulsterone: an old approach to a new problem. *Trends in Endocrinology and Metabolism*, 13(7), 275–276.

[https://doi.org/10.1016/s1043-2760\(02\)00640-9](https://doi.org/10.1016/s1043-2760(02)00640-9)

Urizar, N. L., Liverman, A. B., Dodds, D. T., Silva, F. V., Ordentlich, P., Yan, Y., Gonzalez, F. J., Heyman, R. A., Mangelsdorf, D. J., & Moore, D. D. (2002). A

Synergistic anti-prostate cancer activity of Withaferin-A and Guggulsterone-Z from Ashwagandha and Guggul through inhibition of the NIK/NF- κ B signalling pathway

Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR. *Science*, 296(5573), 1703–1706. <https://doi.org/10.1126/science.1072891>

Singh, S. V., Choi, S., Zeng, Y., Hahm, E.-R., & Xiao, D. (2007). Guggulsterone-Induced Apoptosis in Human Prostate Cancer Cells Is Caused by Reactive Oxygen Intermediate-Dependent Activation of c-Jun NH2-Terminal Kinase. *Cancer Research*, 67(15), 7439–7449. <https://doi.org/10.1158/0008-5472.can-07-0120>

Karin, M. (2006). Nuclear factor- κ B in cancer development and progression. *Nature*, 441(7092), 431–436. <https://doi.org/10.1038/nature04870>

Gupta, S. C., Sundaram, C., Reuter, S., & Aggarwal, B. B. (2010). Inhibiting NF- κ B Activation by Small Molecules As a Therapeutic Strategy. *Biochimica et*

Biophysica Acta, 1799(10-12), 775–787. <https://doi.org/10.1016/j.bbagr.2010.05.004>

Lessard, L., Karakiewicz, P. I., Bellon-Gagnon, P., Alam-Fahmy, M., Ismail, H. A., Mes-Masson, A.-M., & Saad, F. (2006). Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*, 12(19), 5741–5745. <https://doi.org/10.1158/1078-0432.CCR-06-0330>

Jain, G., Cronauer, M. V., Schrader, M., Möller, P., & Marienfeld, R. B. (2011). NF- κ B signaling in prostate cancer: A promising therapeutic target? *World Journal of Urology*, 30(3), 303–310. <https://doi.org/10.1007/s00345-011-0792-y>